Immediate Impact

62 hit
Sub-graph 1 of 24

Citing Papers

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
2024 Hit
Drug resistance in ovarian cancer: from mechanism to clinical trial
2024 Hit
2 intermediate papers

Works of Sarah Farooq being referenced

Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.
2017
TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).
2017

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sarah Farooq 64 32 25 19 11 10 84
Rachael B. Rowswell-Turner 69 1.1× 37 1.2× 19 0.8× 47 2.5× 8 0.7× 14 215
Eugenia Ortega 43 0.7× 20 0.6× 25 1.0× 42 2.2× 24 2.2× 9 113
Maria Grazia Razeti 117 1.8× 93 2.9× 20 0.8× 25 1.3× 9 0.8× 17 227
Yuemei Wang 48 0.8× 56 1.8× 6 0.2× 10 0.5× 13 1.2× 12 80
Rachele Rosati 49 0.8× 36 1.1× 20 0.8× 62 3.3× 6 0.5× 12 106
Nathalie Bonnin 27 0.4× 17 0.5× 26 1.0× 54 2.8× 12 1.1× 12 100
Angela Jain 23 0.4× 34 1.1× 12 0.5× 20 1.1× 14 1.3× 14 67
Ana Santaballa Bertrán 30 0.5× 39 1.2× 9 0.4× 18 0.9× 9 0.8× 11 80
Alvin S.T. Lim 20 0.3× 89 2.8× 25 1.0× 64 3.4× 5 0.5× 11 218
Tomoko Kaneyasu 35 0.5× 15 0.5× 15 0.6× 92 4.8× 8 0.7× 8 231

All Works

Loading papers...

Rankless by CCL
2026